Impact of European pharmaceutical TNCs on the configuration of national economies of the EU
Keywords:
transnational corporation (TNC), the pharmaceutical industry, the national economy, blockbuster drugsAbstract
The article examines the trends and prospects for the development of the pharmaceutical industry of the European Union, describes the main catalysts and threats of further development. It was identified opportunities and threats of the main engines of the pharmaceutical sector of the EU – European pharmaceutical TNCs, justified priorities of the transformation model of their activities, analysed the impact of European pharmaceutical TNCs on the configuration of the national economies of the EU. Particular attention was paid to the threat of the focus of European pharmaceutical TNCs on business strategy, taking advantage of the introduction of blockbuster drugs, which is non-effective for the long term. On the basis of theoretical and statistical material it was offered proposals to pursue opportunities and eliminate threats in the external environment of pharmaceutical TNCs activities in the EU due to the use of their strengths and overcoming weaknesses.References
The Pharmaceutical Industry in Figures // The European federation of pharmaceutical Industries and Associations. – 2014 – 28p.
Global Outlook for Medicines Through 2018. – November 2014
The 2013 EU Industrial R&D Investment Scoreboard // JRc/Dg Research & Innovation of European Commission. – 2013. – 45р.
The Pharmaceutical Industry in Figures // The European federation of pharmaceutical Industries and Associations. – 2013. – 28p.
Beyond borders. Biotechnology Industry Report 2014 // Ernst&Young. – 2014 – 103 p.
Солодковський Ю., Довженко О. Перспективи трансформації сучасної моделі світового фармацевтичного ринку / Ю.Солодковський, О.Довженко // Міжнародна економічна політика. – 2012. –№ 1-2. – С.134-152
Рейтинг «Fortune Global 500» 2014 року. – [Електронний ресурс]. – Джерело доступу: http://fortune.com/
Clinton P., Mozeson M. Top 50 Pharmaceutical companies // Pharmaceutical executive. – 2010. – May. – p.68-80
Cacciotti J., Clinton P. The Lull between two storms // Pharmaceutical executive. – 2011. – May. – p.40-58
Clinton P., Cacciotti J. Growth up from the bottom // Pharmaceutical executive. – 2012. – May. – p.24-34
Noor W., Kleinrock M. Top 50 Pharmaceutical companies // Pharmaceutical executive. – 2013. – May. – 7 p.
Noor W., Kleinrock M. Pharma 50 Insight: The Accelerating Growth of Specialty Markets // Pharmaceutical executive. – 2014. – June. – 8 p.
Competitiveness of the EU Market and Industry for Pharmaceuticals. Volume IІ: Markets, Innovation & Regulation. Final report. – 2009. – 112 р.
Novartis International AG. – [Електронний ресурс]. – Джерело доступу: http://www.novartis.com/
AstraZeneca plc. – [Електронний ресурс]. – Джерело доступу: http://www.astrazeneca.com/
